Agenus
AGEN today
announced that it has entered into a definitive agreement to acquire
4-Antibody AG, a private European-based biopharmaceutical company.
4-Antibody has a technology platform for the rapid discovery and
optimization of fully-human antibodies against a wide array of molecular
targets of interest. These targets include checkpoint molecules that
regulate immune response to cancers and other diseases. The company has
multiple preclinical immune checkpoint antibody programs targeting
numerous checkpoint molecules, including GITR
and OX40,
as well as four additional undisclosed checkpoint programs. These
checkpoint programs are being pursued through a strategic collaboration
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in